Analysts Maintain Buy Ratings Despite Candel Therapeutics’ Volatility Candel Therapeutics continues to receive positive analyst sentiment, with a consensus Buy rating from multiple research reports. Despite recent price swings and a negative earnings outlook, analysts expect earnings per share to improve next year. The company’s high price-to-book ratio, however, suggests the stock may be trading above asset value.12